Moderna (MRNA) Stock Analysis & AI Equity Report
Moderna (MRNA) overview
Moderna (MRNA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,944m and operating profit of USD -3,074m; the year-end share price was 29.49 USD and market capitalisation was USD 11,619m. Moderna is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Moderna's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Moderna
Moderna develops mRNA medicines, including vaccines and therapeutic candidates for infectious diseases, oncology, and rare diseases. Its commercial products include Spikevax and mNEXSPIKE COVID vaccines and mRESVIA, a vaccine against respiratory syncytial virus. The company also advances clinical candidates, including cancer therapies and treatments for rare diseases, and operates manufacturing facilities supporting vaccine launches and collaborations.
Generate the Moderna report
Moderna is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Moderna and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Moderna
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.